Gaoqian Feng1,2, Michelle J Boyle1, Nadia Cross1, Jo-Anne Chan1, Linda Reiling1, Faith Osier1,3,4, Danielle I Stanisic5, Ivo Mueller6, Robin F Anders7, James S McCarthy8, Jack S Richards1,2,9, James G Beeson1,2,9. 1. Burnet Institute, Melbourne. 2. Department of Medicine, University of Melbourne, Parkville, Australia. 3. Centre for Geographic Medicine - Coast, Kenya Medical Research Institute, Kilifi, Kenya. 4. Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg, Germany. 5. Institute for Glycomics, Griffith University, Southport. 6. Walter and Eliza Hall Institute of Medical Research, Parkville. 7. Department of Biochemistry and Genetics, La Trobe University, Melbourne. 8. Clinical Tropical Medicine Laboratory, Queensland Institute of Medical Research Berghofer Medical Research Institute, Herston. 9. Central Clinical School and Department of Microbiology, Monash University, Melbourne, Australia.
Abstract
Background: Overcoming antigenic diversity is a key challenge in the development of effective Plasmodium falciparum malaria vaccines. Strategies that promote the generation of antibodies targeting conserved epitopes of vaccine antigens may provide protection against diverse parasites strains. Understanding differences between vaccine-induced and naturally acquired immunity is important to achieving this goal. Methods: We analyzed antibodies generated in a phase 1 human vaccine trial, MSP2-C1, which included 2 allelic forms of MSP2, an abundant vaccine antigen on the merozoite surface. Vaccine-induced responses were assessed for functional activity against multiple parasite strains, and cross-reactivity of antibodies was determined using competition ELISA and epitope mapping approaches. Results: Vaccination induced cytophilic antibody responses with strain-transcending opsonic phagocytosis and complement-fixing function. In contrast to antibodies acquired via natural infection, vaccine-induced antibodies were directed towards conserved epitopes at the C-terminus of MSP2, whereas naturally acquired antibodies mainly targeted polymorphic epitopes. Functional activity of C-terminal-targeted antibodies was confirmed using monoclonal antibodies that promoted opsonic phagocytosis against multiple parasite strains. Conclusion: Vaccination generated markedly different responses to polymorphic antigens than naturally acquired immunity and targeted conserved functional epitopes. Induction of antibodies targeting conserved regions of malaria antigens provides a promising vaccine strategy to overcome antigenic diversity for developing effective malaria vaccines.
Background: Overcoming antigenic diversity is a key challenge in the development of effective Plasmodium falciparum malaria vaccines. Strategies that promote the generation of antibodies targeting conserved epitopes of vaccine antigens may provide protection against diverse parasites strains. Understanding differences between vaccine-induced and naturally acquired immunity is important to achieving this goal. Methods: We analyzed antibodies generated in a phase 1 human vaccine trial, MSP2-C1, which included 2 allelic forms of MSP2, an abundant vaccine antigen on the merozoite surface. Vaccine-induced responses were assessed for functional activity against multiple parasite strains, and cross-reactivity of antibodies was determined using competition ELISA and epitope mapping approaches. Results: Vaccination induced cytophilic antibody responses with strain-transcending opsonic phagocytosis and complement-fixing function. In contrast to antibodies acquired via natural infection, vaccine-induced antibodies were directed towards conserved epitopes at the C-terminus of MSP2, whereas naturally acquired antibodies mainly targeted polymorphic epitopes. Functional activity of C-terminal-targeted antibodies was confirmed using monoclonal antibodies that promoted opsonic phagocytosis against multiple parasite strains. Conclusion: Vaccination generated markedly different responses to polymorphic antigens than naturally acquired immunity and targeted conserved functional epitopes. Induction of antibodies targeting conserved regions of malaria antigens provides a promising vaccine strategy to overcome antigenic diversity for developing effective malaria vaccines.
Authors: Christian Flueck; Géraldine Frank; Thomas Smith; Ali Jafarshad; Issa Nebie; Sodiomon B Sirima; Sope Olugbile; Pedro Alonso; Marcel Tanner; Pierre Druilhe; Ingrid Felger; Giampietro Corradin Journal: Vaccine Date: 2009-03-06 Impact factor: 3.641
Authors: D E Neafsey; M Juraska; T Bedford; D Benkeser; C Valim; A Griggs; M Lievens; S Abdulla; S Adjei; T Agbenyega; S T Agnandji; P Aide; S Anderson; D Ansong; J J Aponte; K P Asante; P Bejon; A J Birkett; M Bruls; K M Connolly; U D'Alessandro; C Dobaño; S Gesase; B Greenwood; J Grimsby; H Tinto; M J Hamel; I Hoffman; P Kamthunzi; S Kariuki; P G Kremsner; A Leach; B Lell; N J Lennon; J Lusingu; K Marsh; F Martinson; J T Molel; E L Moss; P Njuguna; C F Ockenhouse; B Ragama Ogutu; W Otieno; L Otieno; K Otieno; S Owusu-Agyei; D J Park; K Pellé; D Robbins; C Russ; E M Ryan; J Sacarlal; B Sogoloff; H Sorgho; M Tanner; T Theander; I Valea; S K Volkman; Q Yu; D Lapierre; B W Birren; P B Gilbert; D F Wirth Journal: N Engl J Med Date: 2015-10-21 Impact factor: 91.245
Authors: Paul R Gilson; Thomas Nebl; Damjan Vukcevic; Robert L Moritz; Tobias Sargeant; Terence P Speed; Louis Schofield; Brendan S Crabb Journal: Mol Cell Proteomics Date: 2006-04-07 Impact factor: 5.911
Authors: Christopher G Adda; Christopher A MacRaild; Linda Reiling; Kaye Wycherley; Michelle J Boyle; Vivian Kienzle; Paul Masendycz; Michael Foley; James G Beeson; Raymond S Norton; Robin F Anders Journal: Infect Immun Date: 2012-09-10 Impact factor: 3.441
Authors: Pascal Michon; Jennifer L Cole-Tobian; Elijah Dabod; Sonja Schoepflin; Jennifer Igu; Melinda Susapu; Nandao Tarongka; Peter A Zimmerman; John C Reeder; James G Beeson; Louis Schofield; Christopher L King; Ivo Mueller Journal: Am J Trop Med Hyg Date: 2007-06 Impact factor: 2.345
Authors: James S McCarthy; Joanne Marjason; Suzanne Elliott; Paul Fahey; Gilles Bang; Elissa Malkin; Eveline Tierney; Hayley Aked-Hurditch; Christopher Adda; Nadia Cross; Jack S Richards; Freya J I Fowkes; Michelle J Boyle; Carole Long; Pierre Druilhe; James G Beeson; Robin F Anders Journal: PLoS One Date: 2011-09-19 Impact factor: 3.240
Authors: Bankala Krishnarjuna; Dean Andrew; Christopher A MacRaild; Rodrigo A V Morales; James G Beeson; Robin F Anders; Jack S Richards; Raymond S Norton Journal: Sci Rep Date: 2016-02-11 Impact factor: 4.379
Authors: Damien R Drew; Anthony N Hodder; Danny W Wilson; Michael Foley; Ivo Mueller; Peter M Siba; Arlene E Dent; Alan F Cowman; James G Beeson Journal: PLoS One Date: 2012-12-05 Impact factor: 3.240
Authors: Damien R Drew; Danny W Wilson; Salenna R Elliott; Nadia Cross; Ulrich Terheggen; Anthony N Hodder; Peter M Siba; Kiprotich Chelimo; Arlene E Dent; James W Kazura; Ivo Mueller; James G Beeson Journal: BMC Med Date: 2016-09-23 Impact factor: 8.775
Authors: Jo-Anne Chan; Jessica R Loughland; Lauren de la Parte; Satomi Okano; Isaac Ssewanyana; Mayimuna Nalubega; Felistas Nankya; Kenneth Musinguzi; John Rek; Emmanuel Arinaitwe; Peta Tipping; Peter Bourke; Dean Andrew; Nicholas Dooley; Arya SheelaNair; Bruce D Wines; P Mark Hogarth; James G Beeson; Bryan Greenhouse; Grant Dorsey; Moses Kamya; Gunter Hartel; Gabriela Minigo; Margaret Feeney; Prasanna Jagannathan; Michelle J Boyle Journal: Nat Commun Date: 2022-07-18 Impact factor: 17.694
Authors: Linda Reiling; Michelle J Boyle; Michael T White; Danny W Wilson; Gaoqian Feng; Rupert Weaver; D Herbert Opi; Kristina E M Persson; Jack S Richards; Peter M Siba; Freya J I Fowkes; Eizo Takashima; Takafumi Tsuboi; Ivo Mueller; James G Beeson Journal: Nat Commun Date: 2019-02-05 Impact factor: 14.919
Authors: Damian A Oyong; Enny Kenangalem; Jeanne R Poespoprodjo; James G Beeson; Nicholas M Anstey; Ric N Price; Michelle J Boyle Journal: JCI Insight Date: 2018-11-15
Authors: Liriye Kurtovic; Michelle J Boyle; D Herbert Opi; Alexander T Kennedy; Wai-Hong Tham; Linda Reiling; Jo-Anne Chan; James G Beeson Journal: Immunol Rev Date: 2019-09-26 Impact factor: 12.988
Authors: S J Patgiri; K Sarma; N Sarmah; N Bhattacharyya; D K Sarma; T Nirmolia; D R Bhattacharyya; P K Mohapatra; D Bansal; P K Bharti; R Sehgal; J Mahanta; A A Sultan Journal: Sci Rep Date: 2019-09-23 Impact factor: 4.379